Recent Updates
Recently added Catalysts
ANGO Positive Sentiment

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AngioDynamics published DIRECT study results in The Oncologist and secured a new Category I CPT code for pancreatic IRE. The company highlighted the NanoKnife System's role in expanding cancer treatment options. These milestones support the non-thermal ablation technology's clinical adoption.

Market Sentiment Analysis

POSITIVE FACTORS

  • Publication of DIRECT study results in The Oncologist.
  • New Category I CPT code for pancreatic IRE.
  • Advancements in cancer treatment options.
  • Focus on improving patient quality of life.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
Medium dilution risk
Lead asset
RF ablation
Phase 2 · Non Small Cell Lung Cancer

Full Press Release Details

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in

Frequently Asked Questions

What is the DIRECT study about?

The DIRECT study evaluates the effectiveness of irreversible electroporation (IRE) using the NanoKnife System.

What new code did AngioDynamics receive?

AngioDynamics received a new Category I CPT code for pancreatic IRE.

Where were the DIRECT study results published?

The results were published in The Oncologist.

What technology does the NanoKnife System use?

The NanoKnife System uses non-thermal ablation technology for cancer treatment.

ShareAdd on Google
Tags: ANGO AngioDynamics DIRECT study pancreatic IRE NanoKnife System CPT code
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$34M liquidity · $5M/mo burn
~6 mo
Medium dilution risk
Lead asset
RF ablationPhase 2
Non Small Cell Lung Cancer →